Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Inovio Pharmaceuticals Inc. closed 86.10% short of its 52-week high of $14.75, which the company achieved on April 1st.
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40
Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...
Morningstar4d
Inovio Pharmaceuticals Inc INO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Insider Monkey9d
Inovio Pharmaceuticals Inc. (INO)
Operator: Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. Please note, this event is being recorded. Operator: Good day and welcome ...
Le Lézard5d
Monkey See, Monkey Sue: Alpha Genesis Condemns PETA for Filing First Amendment Lawsuit on Behalf of Monkeys
The lawsuit consumes valuable taxpayer-funded resources. YEMASSEE, SOUTH CAROLINA / ACCESS Newswire / March 11, 2025 / Alpha ...
Le Lézard6d
Buyback of Class B shares in Essity during week 10, 2025
Between March 3, 2025, and March 7, 2025, Essity Aktiebolag (publ) repurchased a total of 270,000 own Class B shares (ISIN: SE0009922164) under the framework of the buyback program as resolved by the ...